WO2026133245 - CARBON 13-LABELLED TAGGANT FOR DETERMINING ADHERENCE TO OR UNAUTHORISED USE OF A PHARMACEUTICAL DOSAGE REGIMEN
National phase entry is expected:
Publication Number
WO/2026/133245
Publication Date
25.06.2026
International Application No.
PCT/IB2025/063168
International Filing Date
18.12.2025
Title **
[English]
CARBON 13-LABELLED TAGGANT FOR DETERMINING ADHERENCE TO OR UNAUTHORISED USE OF A PHARMACEUTICAL DOSAGE REGIMEN
[French]
TRACEUR MARQUÉ AU CARBONE 13 POUR DÉTERMINER L'OBSERVANCE D'UN RÉGIME POSOLOGIQUE PHARMACEUTIQUE OU L'UTILISATION NON AUTORISÉE D'UN RÉGIME POSOLOGIQUE PHARMACEUTIQUE
Applicants **
M MCCUE CONSULTING LLC
Inventors
MCCUE, Marshall
Priority Data
2418683.5
19.12.2024
GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2203 | |
| EPO | Filing, Examination, Granting | 10588 | |
| Japan | Filing, Examination, Granting | 2309 | |
| South Korea | Filing, Examination, Granting | 2410 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
22,850
Contact Us
Abstract[English]
The present invention relates to a pharmaceutical composition comprising a biologically active agent and one or more carbon 13 labelled taggant as defined herein. The present invention further relates to a method of determining adherence to, or unauthorised use of, a pharmaceutical dosage regimen comprising use of said pharmaceutical composition, a system for identifying use of a biologically active agent, and the use of a taggant as defined herein for preparation of said pharmaceutical composition. In one aspect, the taggant is a compound of formula (1): or a pharmaceutically acceptable salt thereof, and wherein the compound of formula (1) contains at least one carbon 13 atom.[French]
La présente invention concerne une composition pharmaceutique comprenant un agent biologiquement actif et un ou plusieurs traceurs marqués au carbone 13 tels que définis dans le présent mémoire de brevet. La présente invention concerne en outre un procédé de détermination de l'observance d'un régime posologique pharmaceutique ou de l'utilisation non autorisée d'un régime posologique pharmaceutique comprenant l'utilisation de ladite composition pharmaceutique, un système pour identifier l'utilisation d'un agent biologiquement actif, et l'utilisation d'un traceur tel que défini dans le présent mémoire de brevet pour la préparation de ladite composition pharmaceutique. Selon un aspect, le traceur est un composé de formule (1) : ou un sel pharmaceutiquement acceptable de celui-ci, le composé de formule (1) contenant au moins un atome de carbone 13.